Health and Healthcare
Why This Schizophrenia Treatment Approval Is Such a Big Deal
Published:
Intra-Cellular Therapy Inc. (NASDAQ: ITCI) shares practically doubled on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta for the treatment of schizophrenia in adults.
Schizophrenia is a serious mental illness affecting roughly 2.4 million adults in the United States. The clinical presentation of schizophrenia is diverse. Acute episodes are characterized by psychotic symptoms, including hallucinations and delusions, often requiring hospitalization. The disease is chronic and lifelong, often accompanied by depression and gradual deterioration of social functioning and cognitive ability. Patients with schizophrenia often discontinue treatment as a result of side effects such as weight gain and movement disorders.
The efficacy of Caplyta at the 42 mg dose was demonstrated in two placebo-controlled trials, showing a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale total score.
Additionally, the most common adverse reactions (≥5% and twice the rate of placebo) for the recommended dose of Caplyta versus the placebo were somnolence/sedation (24% versus 10%) and dry mouth (6% versus 2%).
Jeffrey A. Lieberman, M.D., Lawrence C. Kolb Professor and Chairman of Psychiatry, Columbia University, College of Physicians and Surgeons and Director, New York State Psychiatric Institute, commented:
Schizophrenia is a complex disease that severely impacts patients and their families. Effective treatment provided in a timely fashion can be game-changing for people living with schizophrenia. The efficacy and safety profile of CAPLYTA approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia.
Shares of Intra-Cellular were last seen up about 118% to $27.09, in a 52-week range of $6.75 to $28.60. The consensus price target is $25.22
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
